Yongchang Zhang

46PUBLICATIONS
128CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Jun 24, 2026
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

|Apr 21, 2026
Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.

|Feb 05, 2026
Integrating single-nucleus barcoding with spatial transcriptomics via Stamp-seq to reveal immunotherapy response-enhancing functional modules in NSCLC.

Yitong Pan, Huan Yan, Jinhuan Han

|Feb 02, 2026
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Zhe Huang, Liang Zeng, Zhaohui Ruan

|Dec 15, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

Liang Zeng, Zhaohui Ruan, Huan Yan

|Dec 15, 2025
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.

Pasquale F Innominato, Thierry Landré, Abdoulaye Karaboué

Pageof 8

Frequent Collaborators

7 joint publications

Chengzhi Zhou

7 joint publications

Wenxian Wang

7 joint publications

Chunwei Xu

6 joint publications

Zhansheng Jiang